NCT00244231 is a Phase 3 clinical trial of Nidadd in Hyperlipidemia, sponsored by Genovate Biotechnology Co., Ltd.,.

Who is sponsoring NCT00244231?

NCT00244231 is sponsored by Genovate Biotechnology Co., Ltd.,.

What drugs are being tested in NCT00244231?

Interventions in NCT00244231: Nidadd.

What condition does NCT00244231 study?

NCT00244231 studies Hyperlipidemia.

Is NCT00244231 still recruiting?

NCT00244231 is currently completed. Last updated 27 February 2007.

Last reviewed 2007-02-27 · How we verify

NCT00244231

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Placebo-Controlled, Double Blind Study to Evaluate the Efficacy and Safety of Nidadd in the Management of Hyperlipidemia

Completed Phase 3 Last updated 27 February 2007

What this trial tests

Phase 3 trial testing Nidadd in Hyperlipidemia in 70 participants. Completed in 1 August 2005.

Timeline

1 October 2003

1 August 2005

Quick facts

Lead sponsor	Genovate Biotechnology Co., Ltd.,
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	70
Start date	1 October 2003
Estimated completion	1 August 2005

Drugs / interventions tested

Nidadd — full drug profile →

Conditions studied

Hyperlipidemia — all drugs for Hyperlipidemia →

Sponsor

Genovate Biotechnology Co., Ltd., — full company profile →

Who can join

Adults 20 to 75, any sex, with Hyperlipidemia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change from baseline in HDL-c levels

Sponsor's own description

To assess the efficacy and safety of Nidadd (extended-release niacin) in patients with hyperlipidemia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

NAD<sup>+</sup> metabolism: pathophysiologic mechanisms and therapeutic potential.
Xie N, Zhang L, Gao W, Huang C, et al · · 2020 · cited 744× · PMID 33028824 · DOI 10.1038/s41392-020-00311-7

Verify or expand the search:

Other recruiting trials for Hyperlipidemia

Currently open trials in the same condition.

NCT06966258 — Inspire HER: Inspiring the Heart and Emotions for Radical Health · NA · recruiting
NCT07216482 — A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) · Phase 3 · recruiting
NCT06615609 — "Smart Family Doctor" Assisted Comprehensive Management of Secondary Prevention Among Post Coronary Artery Bypass Graft · NA · recruiting
NCT07400549 — Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support T · NA · recruiting
NCT06603363 — Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT · NA · recruiting

Other Genovate Biotechnology Co., Ltd., trials

Trials by the same sponsor.

NCT06167265 — BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers · Phase 1 · completed
NCT05466734 — BE Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers · Phase 1 · completed
NCT05191862 — Bioequivalence Study of PMR Compared to Cilostazol IR Tablets in Healthy Volunteers · Phase 1 · terminated
NCT03864666 — Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers · Phase 1 · completed
NCT03480321 — Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00244231 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Genovate Biotechnology Co., Ltd.,
Last refreshed: 27 February 2007

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00244231.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing